Could this vaccine stop all coronaviruses? early trial begins
NCT ID NCT06950177
First seen Nov 05, 2025 · Last updated May 10, 2026 · Updated 23 times
Summary
This early-stage study tests a new vaccine designed to protect against many types of coronaviruses, including COVID-19 and its variants. It involves 51 healthy adults aged 18-55 who will receive two doses. The main goal is to check safety and how well the vaccine triggers an immune response.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SARS-COV-2 INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Duke University Health System
Durham, North Carolina, 27709, United States
Conditions
Explore the condition pages connected to this study.